AGENT FOR THE TREATMENT OF MALIGNANT DISEASES

摘要

The invention relates to an agent for treating tumor diseases such as multiple myeloma. Said agent acts upon NK cells by activating an anti-tumor immune response after stimulating the NKp30 receptor and the natural cytotoxicity receptor (NCR). Said agent comprises a physiologically effective amount of BAT3 protein, BAT3/anti-CD138 protein, BAT3-specific antibodies, or derivatives of said substances in an acceptable carrier material. The invention can also be used for treating CD138-negative tumors according to the same principle of the BAT3/anti-CD138 protein, wherefore the anti-CD138 component containing an antibody fragment is replaced with any tumor antigen, and the corresponding agent is used for treating tumors expressing said tumor antigen. The invention further relates to the use of recombinant BAT3 protein or a BAT3 fragment without an antibody-based fusion component for treating malignant diseases by activating NKp30 and NCR on NK cells. The invention finally relates to the use of BAT3 cDNA for introducing BAT3 in vivo and/or ex vivo into tumor cells, which results in better recognition by NK cells, in immunotherapy of malignant diseases.